Compare Gilead Sciences, Inc. (GILD) vs JPMorgan Ultra Short Income ETF (JPST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs JPMorgan Ultra Short Income ETF — how do they compare? Gilead Sciences, Inc. trades at $133.04 (market cap $163.51B), while JPMorgan Ultra Short Income ETF trades at $50.49. The key difference: Gilead Sciences, Inc. pays a 2.49% dividend while JPMorgan Ultra Short Income ETF pays none, and Gilead Sciences, Inc. is trading nearer its 52-week high, JPMorgan Ultra Short Income ETF nearer its low. Which is the better fit depends on your goals.
| GILD | JPST | |
|---|---|---|
Market Cap | $163.51B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $155.80 | $50.78 |
52-Week Low | $108.22 | $50.40 |
Enterprise Value | $178.05B | — |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $130.04, down 1.04% on the day, with technical indicators showing a bearish bias while fundamentals remain strong. The company has beaten earnings expectations for three consecutive quarters, maintains robust profitability with a 30.99% net income margin, and recently secured FDA and European Commission approvals for expanded use of its oncology drug Trodelvy. Analyst consensus remains overwhelmingly positive with a $152.83 price target representing 17.5% upside potential.
The outlook for GILD is favorable with strong earnings momentum, expanding oncology portfolio, and solid cash generation, though risks include patent expirations, competitive pressures in HIV treatments, and recent negative cash flow trends. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharmaceutical company with growth catalysts, supported by Wall Street's bullish sentiment and recent regulatory wins.
JPST, the JPMorgan Ultra-Short Income ETF, trades at $50.485, up 0.03% on the day. The technical outlook is bearish based on moving averages, though oscillators are neutral. The ETF focuses on high-quality, short-term bonds, offering low duration risk and current income. Recent news highlights strong inflows into active ETFs, with JP Morgan leading in June 2026 flows (ETF Trends, 2026-07-07).
JPST provides a cash-alternative for risk-averse investors, with a stable dividend history. Key risks include interest rate sensitivity and credit spread changes. The fund's conservative profile suits those seeking capital preservation amid market volatility, but limited upside potential exists compared to equity ETFs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About JPMorgan Ultra Short Income ETF
JPST is an actively managed ETF that invests in short-term, investment-grade fixed income securities. It aims to provide current income and capital preservation while maintaining high liquidity.
Read more on JPST →
